Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 3Neoplasm Metastasis 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Tertiary Lymphoid Structures 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Nasopharyngeal Carcinoma 1Mesothelioma, Malignant 1Mesothelioma 1Gallbladder Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Transitional Cell 1Camurati-Engelmann Syndrome 1Breast Neoplasms 1

Interventions

fresolimumab 1bintrafusp alfa protein, human 1ascrinvacumab 1Trabedersen 1Temozolomide 1Sorafenib 1Radiotherapy 1Losartan 1Lomustine 1LY-2157299 1Drug Delivery Systems 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Camurati-Engelmann Syndrome × bintrafusp alfa protein, human × Clear all
NCT03833661 2023-10-25

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

EMD Serono

Phase 2 Completed
159 enrolled 23 charts
Gastrointestinal

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡